Hypogammaglobulinemia and infection rates in patients with multiple sclerosis treated with ocrelizumab for up to six years: A real-world single-center study
{{output}}
Objectives and aims: Ocrelizumab (OCR) is disease-modifying therapy that depletes B cells for the treatment of patients with relapsing and progressive multiple sclerosis (MS). The aim of this study was to evaluate occurrence of h... ...
